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Abstract
Renal lysosomes play a major role in catabolism of plasma proteins. Final products of this catabolism include dipeptides
and tripeptides that must be exported to the cytosol for hydrolysis. The aim of the present study was to determine whether an
oligopeptide transporter is present in the renal lysosomal membrane that could mediate this export. The existence of an
oligopeptide transporter was probed with the uptake of glycylglutamine (Gly-Gln) by membrane vesicles prepared from renal
lysosomes. Kinetic analysis showed the presence of a single transporter with a Km of 8.77 mM for the uptake of Gly-Gln. The
Gly-Gln uptake was energized by the imposition of an inwardly directed proton gradient (pHout 5.0/pHin 7.3) and membrane
potential (outside positive/inside negative) resulting in overshoot. The Gly-Gln uptake was inhibited by the presence of
dipeptides and tripeptides, but not amino acids. Western blot analysis of lysosomal membrane proteins with Pept-1 (an
oligopeptide transporter) antibody as the probe showed the presence of an immunoreactive protein. This immunoreaction
was abolished when the antiserum was preabsorbed with the Pept-1 epitope (0.5 Wg/ml). In conclusion, the present data show
the existence of a low-affinity dipeptide transporter in the renal lysosomal membrane that appears to belong to the Pept
family of transporters. The function of this transporter appears to be to prevent accumulation of dipeptides in renal
lysosomes. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
We recently reported the presence of an oligopep-
tide transporter in hepatic lysosomal membrane [1].
A key question that follows this discovery is whether
this transporter is unique to the liver lysosomes, or is
it present in other lysosomes. Among the extra-
hepatic tissues, kidney is the most likely tissue to
have a lysosomal oligopeptide transporter. Kidney is
the site for large-scale degradation of plasma pro-
teins, for example, over 8 g of plasma albumin are
catabolized daily in this site [2]. After ¢ltration
across glomeruli, 99% of plasma proteins are reab-
sorbed via the renal proximal tubules by endocytosis
[2]. After endocytosis, the plasma proteins are deliv-
ered to lysosomes for degradation [2]. The ¢nal prod-
ucts of lysosomal degradation of proteins include
small peptides, mostly dipeptides [3].
These products must be exported to the cytoplasm
in order to prevent osmotically-induced swelling and
rupture of lysosomes. The objective of the present
study was to determine whether renal lysosomes con-
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tain an oligopeptide transporter, and, if so, to eluci-
date its characteristics. The presence of a transporter
was probed with the uptake of glycylglutamine (Gly-
Gln) by membrane vesicles of renal lysosomes.
2. Materials and methods
2.1. Materials
Adult male rats (250^300 g) were purchased from
Harlan Sprague-Dawley (Indianapolis, IN). Custom
synthesized [glutamine-3,4-3H]glycylglutamine (49 Ci/
mmol) was obtained from New England Nuclear
(Boston, MA). Filters (type HAWP, 0.45 Wm pore
size) were purchased from Millipore Corp. (Bedford,
MA). Cefadroxil and other chemicals were purchased
from Sigma (St. Louis, MO).
2.2. Preparation of lysosomal membrane vesicles
(LMV)
The kidneys were removed immediately after rats
were killed. LMV were prepared as described previ-
ously [1]. Brie£y, kidneys were cut into small pieces
and homogenized in bu¡er 1 (250 mM sucrose,
20 mM HEPES/Tris, 1 mM EDTA, pH 7.0) contain-
ing 1 Wg/ml pepstatin and 2 Wg/ml leupeptin, using a
Dounce homogenizer. The kidney homogenate was
centrifuged for 20 min at 500Ug to eliminate the
nuclear pellet. The resulting supernatant was centri-
fuged for 30 min at 20 000Ug and the pellet was
resuspended in bu¡er 2 (250 mM sucrose, 20 mM
HEPES/Tris, pH 7.0). The suspension was mixed
with isotonic Percoll (2.5 M sucrose and 200 mM
HEPES/Tris, pH 7.0, mixed with Percoll at 1:9) in
the ratio of 9:11. The Percoll mixture was centri-
fuged for 90 min at 40 000Ug. The brownish lysoso-
mal band near the bottom of the gradient was iso-
lated. LMV were prepared by incubation of
lysosomes in bu¡er 2 containing 5 mM methionine
methyl ester, 2 mg/ml bovine serum albumin and
2 mM magnesium chloride for 20 min at 37‡C. An
equal volume of ice-cold isotonic Percoll was added
to the incubation mixture and the mixture was cen-
trifuged at 35 000Ug for 30 min. Puri¢ed LMV were
located on the top of this dense gradient as a brown-
ish band. Finally, LMV were diluted in preloading
bu¡er (100 mM KCl, 100 mM mannitol, 20 mM
HEPES/Tris, pH 7.3) and used in uptake experi-
ments. The protein concentration was measured by
the Bio-Rad protein assay (Bio-Rad Laboratories,
Hercules, CA). The purity of the LMV preparation
was determined as described previously [1]. The ac-
tivities of L-hexosaminidase, cytochrome c oxidase,
and 5P-nucleotidase in kidney homogenate and
vesicle preparation were measured by methods de-
scribed previously [1].
2.3. Gly-Gln uptake
The uptake of Gly-Gln by LMV was measured by
rapid ¢ltration technique as described previously [4].
Brie£y, after preincubation with valinomycin at
room temperature for 30 min, 20 Wl of LMV suspen-
sion (LMV in preloading bu¡er) was mixed with
180 Wl of transport bu¡er containing Gly-3H-Gln.
Since the composition of the transport bu¡ers varied,
each is described in the relevant ¢gure legend. The
mixtures were incubated at 23‡C for various prede-
termined lengths of time. The uptake was terminated
by injecting 200 Wl of this vesicle mixture to 2 ml of
ice-cold stop solution (same composition as the
transport bu¡er, but without Gly-3H-Gln) and ¢l-
tered immediately (0.45 Wm pore). The ¢lters were
then washed with 5 ml of ice-cold stop solution
and the associated radioactivity was counted by scin-
tillation spectrometer.
2.4. Western blot analysis
A Western blot analysis of LMV proteins was per-
formed with Pept-1 antibody as the probe. The fol-
lowing technique was used to prepare Pept-1 anti-
body. Based on the molecular structure of rat Pept-
1, a synthetic peptide (Glu-Asn-Pro-Tyr-Ser-Ser-Leu-
Glu-Pro-Val-Ser-Gln-Thr-Asn-Met) corresponding
to the 15 carboxy-terminal amino acids (696^710)
was used as the epitope [5]. The rabbit Pept-1 anti-
body was generated by immunization of rabbit with
this epitope, and the speci¢city of the antibody was
con¢rmed by Western blot analysis with the anti-
body that had been preabsorbed with the epitope
(0.5 Wg/ml).
LMV from kidney and liver were denatured, sub-
jected to 10% SDS-polyacrylamide gel electrophore-
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sis, and transferred onto a nitrocellulose membrane.
The nitrocellulose membrane was blocked in 10%
non-fat dry milk dissolved in Tris-bu¡ered saline
containing 0.5% Tween 20 (polyoxyethylenesorbitan
monolaurate) (TBST), washed with TBST, and then
incubated with Pept-1 antibody (1:1000). After incu-
bation, the membrane was washed with TBST again,
incubated with the second antibody (peroxidase-con-
jugated goat anti-rabbit IgG, 1:2000) and then de-
tected with ECL Western blotting system (Amersham
Life Science, Arlington Heights, IL).
2.5. Calculation and statistical analysis
Kinetic constants of Gly-Gln transport were deter-
mined by applying a nonlinear regression method to
the Michaelis^Menten kinetic equation using GRA-
FIT (Sigma):
V  VmaxS=Km  S
where V is Gly-Gln uptake in nmol/mg protein/40 s,
S is external Gly-Gln concentration in mM, Vmax is
maximal Gly-Gln uptake, Km is the concentration of
S that yielded one half Vmax. Data are given as
mean þ S.E.M. of at least three replicates. Signi¢cant
di¡erences between values were determined by Stu-
dent’s t-test.
3. Results
3.1. Purity of LMV
Our membrane vesicle preparations showed fold
depletion of both cytochrome c oxidase (a mitochon-
drial marker) and 5P-nucleotidase (a plasma mem-
brane marker) (Table 1). On the other hand, there
was about a 10-fold enrichment of L-hexosaminidase
(a lysosomal marker) in the vesicle preparation (Ta-
ble 1). These results are similar to our previous re-
sults in the liver LMV [1]. In our previous study [1],
we showed 100-fold enrichment of L-glucosidase (a
lysosomal membrane marker) in the liver LMV. This
enrichment determination could not be performed in
the present study because in kidney cells, unlike in
liver cells, L-glucosidase is not present in the lysoso-
mal fraction since it remains in the soluble fraction
during LMV isolation.
3.2. Gly-Gln uptake as a function of time
Evidence suggesting the presence of an active sol-
ute transporter requires the demonstration of an
‘overshoot’ in membrane vesicles. An overshoot is
observed when membrane vesicles transiently accu-
mulate that solute in a concentration that is higher
than its concentration in the incubation medium. To
seek such evidence, we determined Gly-Gln uptake
by renal LMV as a function of time in the presence
and absence of an inwardly directed proton gradient
and membrane potential. In previous studies we have
shown that these conditions are needed for observing
overshoot in transport of dipeptides such as Gly-Gln
[1,4]. It should be noted that at the pH used in this
experiment, Gly-Gln is in a zwitterionic form and,
therefore, carries no net electrical charge.
As shown in Fig. 1, in the absence of a proton
gradient (pHout 7.3/pHin 7.3) Gly-Gln concentration
in LMV progressively increased during the initial
2 min and then remained unchanged for the remain-
ing period of observation. On the other hand, in the
presence of a proton gradient (pHout 5.0/pHin 7.3),
Table 1
Speci¢c activity, yield, and puri¢cation of marker enzymes in LMV
Enzyme Speci¢c activity in homogenate LMV
Speci¢c activity Yield (%) Puri¢cation factor
L-Hexosaminidase 136 þ 6.85 1322 þ 182.7 8.4 9.7
Cytochrome c oxidase 3228 þ 291 199 þ 43.1 0.01 0.06
5P-Nucleotidase 162 þ 28.4 8.12 þ 6.36 6 0.01 0.05
Speci¢c activities are given as mean þ S.D. of at least three assays. Units of enzyme activities are de¢ned as nmol min31 mg protein31
for L-hexosaminidase; Wmol h31 mg protein31 for 5P-nucleotidase; and v(log OD) min31 mg protein31 for cytochrome c oxidase.
Yield is expressed as the percentage of the total activity of the homogenate recovered in the LMV fraction, expressed as the mean of
at least three assays.
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over a three-fold overshoot in Gly-Gln uptake oc-
curred 1 min after the incubation.
As shown in Fig. 1, imposition of a membrane
potential also resulted in over a three-fold overshoot
in Gly-Gln uptake 1 min after the incubation. The
membrane potential was generated by replacing the
KCl in the transport medium with 100 mM choline
chloride while maintaining the KCl concentration in-
side the vesicles at 100 mM. A much greater over-
shoot (over ¢ve-fold) than the ones observed with the
imposition of proton gradient or membrane potential
occurred when these driving forces were combined
(Fig. 1).
3.3. Gly-Gln uptake as a function of osmolarity
To determine the extent of Gly-Gln uptake (Fig. 1)
as transport into membrane vesicles, we determined
Gly-Gln uptake as a function of medium osmolarity.
Osmolarity was varied by addition of sucrose (0^900
mM) to the medium. The results showed a linear
relationship between the rates of uptake and the re-
ciprocal of medium osmolarities (Fig. 2). Since the
osmoplot showed no Gly-Gln uptake at in¢nite os-
molarity (Fig. 2), the uptakes shown in Fig. 1 were
all transport into an osmotically reactive space.
3.4. Gly-Gln uptake as a function of concentration
To determine the kinetic constants of Gly-Gln up-
take by renal LMV, the rates of uptake as a function
of concentration were determined. To cover the Km
of both high- and low-a⁄nity transporters, the con-
centration used ranged from 100 WM to 20 mM.
These data were used to develop an Eadie^Hofstee
plot (Fig. 3). Although the lower concentrations are
not shown, a linear relation between v and v/s was
observed over the entire range of concentration used,
indicating the presence of a single transporter for
Gly-Gln uptake. The calculation of kinetic constants
showed that the transporter has a Km of 8.77 þ 2.72
mM and a Vmax of 11.00 þ 1.45 nmol/mg protein/40 s.
Fig. 2. Gly-Gln uptake as a function of osmolarity. Renal
LMV were preloaded with preloading bu¡er (100 mM KCl, 100
mM mannitol, 20 mM HEPES/Tris, pH 7.3) preincubated with
50 WM valinomycin for 30 min at room temperature, and then
incubated with the transport bu¡er containing 0.1 mM Gly-3H-
Gln, 100 mM mannitol, 100 mM KCl, 20 mM MES/Tris, pH
5.0, and 0^900 mM sucrose for 60 min.
Fig. 1. Gly-Gln uptake as a function of time. Control (a) : Re-
nal LMV were preloaded with preloading bu¡er (100 mM KCl,
100 mM mannitol, 20 mM HEPES/Tris, pH 7.3), preincubated
with 50 WM valinomycin for 30 min at room temperature, and
then incubated with the transport bu¡er containing 0.1 mM
Gly-3H-Gln, 100 mM mannitol, 100 mM KCl, 20 mM HEPES/
Tris, pH 7.3. In presence of proton gradient (b) : conditions
were the same as above, except that the HEPES/Tris, pH 7.3,
was replaced with MES/Tris, pH 5.0, in the transport bu¡er. In
presence of membrane potential (E) : conditions were the same
as those in the absence of proton gradient except that the
100 mM KCl in the transport bu¡er was replaced with 100 mM
choline chloride. In presence of membrane potential plus proton
gradient (R) : conditions were the same as above except that
HEPES/Tris, pH 7.3, in the transport bu¡er was replaced with
MES/Tris, pH 5.0.
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3.5. Inhibition of Gly-Gln uptake
Inhibition pro¢le is commonly used to determine
the substrate speci¢city of a transporter. We, there-
fore, determined inhibition of lysosomal uptake of
Gly-Gln by representative amino acids (glycine and
glutamine), dipeptides (Gly-Gln, Gly-Sar, Gly-Pro),
tripeptides (Gln-Gln-Gly, Gly-Pro-Ala), and a pepti-
domimetic drug (cefadroxil). Glycine and glutamine
had no e¡ect on Gly-Gln transport, but the others
greatly inhibited this transport (Table 2).
3.6. Western blot analysis of the oligopeptide
transporter
To investigate whether the transporter in renal ly-
sosomes belonged to the family of oligopeptide trans-
porters recently cloned, we carried out Western blot
analyses of renal LMV with an antibody against
Pept-1 (Fig. 4). Pept-1 is the brush-border membrane
oligopeptide transporter in the intestinal and renal
epithelium [6,7]. The results showed the presence of
a Pept-1 immunoreactive protein in renal LMV. The
speci¢city of this protein was established by its dis-
appearance when the antiserum was preabsorbed
with the Pept-1 epitope.
Since our previous studies have shown the pres-
ence of an oligopeptide transporter in hepatic LMV
[1], we also carried out Western analyses of hepatic
Fig. 4. Western blot analysis of the transporter. Equal amounts
(100 Wg) of protein from renal and hepatic LMV were loaded
on 10% SDS-polyacrylamide gel. The Pept-1 antibody was used
to probe the oligopeptide transporter in all the above mem-
brane preparations. The peroxidase-conjugated goat anti-rabbit
IgG was used for the detection of bound antibodies and the
blot was visualized by chemiluminescence on X-ray ¢lm.
Table 2
Inhibition of Gly-Gln uptake
Substrate Uptake (%)
Gly-Gln (control) 100
Gly-Gln 0
Gly-Sar 16
Gly-Pro 0
Gly-Gly-Gly 20
Gly-Pro-Ala 0
Glycine 100
Glutamine 100
Cefadroxil 32
Renal LMV were preloaded with preloading bu¡er (100 mM
KCl, 100 mM mannitol, 20 mM HEPES/Tris, pH 7.3), preincu-
bated with 50 WM valinomycin for 30 min at room tempera-
ture, and then incubated for 40 s with the transport bu¡er con-
taining 0.1 mM Gly-3H-Gln, 100 mM mannitol, 100 mM
choline chloride, 20 mM MES/Tris, pH 5, and a possible inhibi-
tor of Gly-Gln uptake at concentration of 30 mM.
Fig. 3. Gly-Gln uptake as a function of substrate concentration.
Renal LMV were preloaded with preloading bu¡er (100 mM
KCl, 100 mM mannitol, 20 mM HEPES/Tris, pH 7.3), preincu-
bated with 50 WM valinomycin for 30 min at room tempera-
ture, and then incubated with the transport bu¡er containing
2^20 mM Gly-3H-Gln, 100 mM mannitol, 100 mM choline
chloride, and 20 mM MES/Tris, pH 5. The insert shows Eadie^
Hofstee transformation of the data; V is the rate of Gly-Gln
uptake (nmol/mg protein/40 s) and S is the concentration of
Gly-Gln in the medium (mM).
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LMV with antibody against Pept-1 as the probe. The
results showed the presence of a Pept-1 immunore-
active protein.
4. Discussion
The present results indicate that liver is not unique
in having a lysosomal oligopeptide transporter since
kidneys appear to have a similar transporter. The
similarity between the hepatic and renal lysosomal
transporters is suggested by the following compari-
son. Both are low a⁄nity transporters (Km in the
mM range). Both are energized by an inwardly di-
rected proton gradient and membrane potential re-
sulting in overshoot (Fig. 1). Both have a similar
inhibition pro¢le, namely inhibition by dipeptides
and tripeptides, but not by amino acids (Table 2).
The question of whether the oligopeptide transporter
is expressed only in the lysosomes of cells with high
rates of protein degradation (for example, liver and
kidney) or ubiquitously expressed in cell lysosomes
cannot be answered until a systematic tissue study is
performed.
A major di¡erence exists between liver and kidney
in the uptake of dipeptides circulating in plasma. The
apical membrane of renal cells contains two trans-
porters for the uptake of dipeptides, which are ¢l-
tered across glomeruli [7], while the sinusoidal mem-
brane of hepatic cells does not have any transporter
for the uptake of dipeptides [8,9]. As a result, renal
cells accumulate dipeptides circulating in plasma,
while hepatic cells do not participate in this metabol-
ic process [10]. Therefore, renal lysosomes, unlike
hepatic lysosomes, could play a substantial role in
the metabolism of circulating dipeptides. However,
our data (here and with hepatic LMV) suggest that
the function of the lysosomal oligopeptide transport-
er is to export rather than to import dipeptides. For
example, conditions such as proton gradient and
membrane potential, which normally exist across ly-
sosomal membrane, favor export and not import of
dipeptides. In fact, in vitro incubation studies have
shown that (a) lysosomes release oligopeptides [11],
and (b) if lysosomes import dipeptides, they are
likely to swell and rupture [12].
Another novel ¢nding of the present study was
that the lysosomal oligopeptide transporter belongs
to the Pept family of transporters recently cloned.
Besides Pept-1, the cloned transporters include
Pept-2, which is located on the brush-border mem-
brane of renal tubular cells [7]. In view of a substan-
tial homology among the oligopeptide transporters,
we speculated that a Pept-1 antibody would recog-
nize the transporter in lysosomes. We chose Pept-1
over Pept-2 antibody because Pept-1, like the lysoso-
mal transporter, is a low a⁄nity transporter while
Pept-2 is a high a⁄nity transporter. This speculation
proved to be productive with our ¢nding of a protein
in the membrane of renal and hepatic lysosomes that
would disappear if antiserum was preabsorbed with
Pept-1 epitope. However, we do not believe that the
lysosomal oligopeptide transporter is actually Pept-1,
because Pept-1 gene expression is absent in the liver
[5,13]. Using the same strategy as we have done in
the present experiment, others [14] have found the
presence of Pept-1 immunoreactive protein in the
lysosomes of acinar cells of the pancreas. However,
whether the lysosomes in the pancreatic acinar cells
are capable of peptide transport was not studied.
Therefore, the signi¢cance of Pept-1 immunoreactive
protein in the lysosomes of acinar cells remains to be
determined.
In conclusion, we suggest that the main function
of the oligopeptide transporter in renal lysosomes is
to provide an active mechanism for the completion
of the ¢nal stage in the catabolism of circulating
proteins. Dipeptides and tripeptides, produced from
this catabolism, are transferred from a region of low
peptidase activity (lysosome) to a region of high pep-
tidase activity (cytosol). This suggestion brings a new
dimension to the concept of catabolism of plasma
proteins in health and in disease.
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